Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (LODR), please find enclosed the transcript of the earnings conference call for the quarter ended June 30, 2023, conducted after the meeting of Board of Directors held on August 14, 2023, for your information and records. Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith copies of newspaper advertisement providing extract of unaudited financial results of the company for the quarter ended June 30, 2023. Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46 of SEBI (LODR) we wish to inform that we have uploaded audio recording of the Q1 of FY24 earnings call held on August 14, 2023, on our company website. Solara Active Pharma Sciences Ltd - 541540 - ''Reconstitution Of Committees Of The Board''.
Pursuant to Regulation 30 of SEBI (LODR), this is to inform you that Board of Directors at their meeting held today (August 14, 2023) have approved and reconstituted the composition of Audit Committee, Risk Mangement Committee and Corporate Social Responsibility Committee. Q1FY24 Quarterly Result Announced for Solara Active Pharma Sciences Ltd.
Pharmaceuticals company Solara Active Pharma Sciences announced Q1FY24 results: Q1FY24 Revenues at Rs 3,544 million up 5% YoY; Reported EBITDA at Rs 200 million up 11% YoY; Gross margins at 45.5% in Q1FY24 versus 41.0% in Q1FY23; YoY Improvement in Gross margins by 445 bps Reported EBITDA at Rs 200 million, EBITDA margins at 5.6%; YoY Improvement in EBITDA margins by 20 bps Reduction in under-recoveries at Vizag Commenting on the financial performance, Poorvank Purohit, MD & CEO of the Company, remarked, “We are delighted to start FY24 on a positive note, after having accomplished many of the goals we set for ourselves at the beginning of the previous year. Our current priorities are to stay focused and move forward from what we had achieved in the last fiscal year. We continue to work on our key strategic priorities, which included resetting and concentrating the base business, restoring R&D; velocity, addressing under-recoveries at our newly commissioned Vizag site, and expanding into new products and geographies. We are happy with the outcome of the USFDA inspection at our Cuddalore facility with Zero 483 inspectional observations. The result of these inspections demonstrates our commitment to regulatory excellence at our global manufacturing sites and our relentless focus on world-class quality and compliance. Coming to the Q1FY24 performance, I am pleased to report that we achieved 5% YoY growth in Revenues and 11% YoY growth in EBITDA. Our order book continues to be strong. We are pleased to note the increase in demand for Ibuprofen and Ibuprofen derivatives. We continue to focus on Operating cost reduction, continuous improvement program (CIP), and inventory management. With a Strong order book position, expansion in margins, and reduced under recovery at Vizag, we have a visible growth momentum for the forthcoming quarters.” Result PDF Solara Active Pharma Sciences Ltd - 541540 - Outcome Board Meeting For Approval Of Unaudited Financial Results For The Quarter Ended June 30, 2023
Unaudited Financial Results for the quarter ended June 30, 2023 along with limited review report and press release is attached. Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, kindly note that the Company, as part of investors engagement activities, has re- scheduled a conference call with the investors and analysts on Monday, August 14, 2023, at 3:30 pm IST to discuss its Q1 financial results. Solara Active Pharma Sciences Ltd - 541540 - Update on board meeting
The Board Meeting to be held on 11/08/2023 has been revised to 14/08/2023 The Board Meeting to be held on 11/08/2023 has been revised to 14/08/2023
Solara Active Pharma Sciences gain on USFDA all-clear for Cuddalore unit
The pharma company also told exchanges that Aditya Puri has resigned as the chairman and non-executive director
